AIP
VIVO

Ahrens Investment Partners’s Meridian Bioscience Inc VIVO Stock Holding History

Ahrens Investment Partners’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500
Closed -$15K – 997
2022
Q2 		$15K Hold
500
– – 0.01% 571
2022
Q1 		$13K Buy
+500
New +$11.9K ﹤0.01% 685

Other funds holding VIVO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ahrens Investment Partners's VIVO Position: Q3 2022 in Review

Ahrens Investment Partners sold out of Meridian Bioscience Inc (VIVO) in Q3 2022, closing a stake of 500 shares — an estimated $15K sold.

Ahrens Investment Partners first reported a position in VIVO in Q1 2022 and held it in 2 quarters. The position peaked at $15K in Q2 2022. 203 funds tracked by Wall St. Rank hold VIVO as of Q3 2022.

  • Ahrens Investment Partners reported no remaining Meridian Bioscience Inc position as of Q3 2022 after selling out during the quarter.
  • Ahrens Investment Partners sold 500 Meridian Bioscience Inc shares in Q3 2022, an estimated $15K.
  • Ahrens Investment Partners first reported a position in Meridian Bioscience Inc in Q1 2022 and held it in 2 quarters.
  • Ahrens Investment Partners's Meridian Bioscience Inc position peaked at $15K in Q2 2022.
  • 203 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2022.

Based on Ahrens Investment Partners's 13F filing for Q3 2022, filed 8 Nov 2022.